approved the first combined inhibitor therapy pill for melanoma: Dabrafenib and trametinib,
designed to block certain BRAF enzyme pathway genetic mutations. These mutations occur in approximately 50%
of melanoma patients ... after one year of clinical trial treatment on the combined pill, Dabrafenib and Trametinib, 41% of melanoma
patients were progress-free compared with only 9% in the monotherapy Dabrafenib